---
title: "Sophoricoside Shows Antiproliferative Activity in Pancreatic Cancer via PTPN1 Targeting"
id: "pubmed-42814531"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42814531"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42814531/"
doi: "10.1002/cbdv.71778"
published_at: "2026-10-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Sophoricoside Shows Antiproliferative Activity in Pancreatic Cancer via PTPN1 Targeting
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42814531
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42814531/)
- **DOI:** [10.1002/cbdv.71778](https://doi.org/10.1002%2Fcbdv.71778)
- **Published At:** 2026-10-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Pancreatic cancer has poor prognosis and few effective therapies; the study tested the natural isoflavone glycoside **sophoricoside (SOP)** for anticancer activity. - SOP reduced proliferation in human pancreatic cancer cell lines MIA PaCa-2, SW1990, and PANC-1 in a dose-dependent manner in cellular assays. - An integrative computational workflow combining **network pharmacology**, machine learning, and multi-omics identified 85 overlapping SOP-related targets and pathway enrichment in **MAPK**, apoptosis, and **PD-L1/PD-1** signaling. - Machine learning and differential expression analyses converged on **PTPN1** (protein tyrosine phosphatase non-receptor type 1) as the core candidate target for SOP in pancreatic adenocarcinoma. - PTPN1 was reported as markedly upregulated in pancreatic adenocarcinoma, with high expression correlating with worse survival and altered immune infiltration patterns according to the source. - Functional enrichment associated PTPN1 with **TGF-β** signaling, **VEGF**, and metabolic reprogramming pathways relevant to tumor biology. - Molecular docking predicted a plausible binding mode between SOP and PTPN1, including four putative hydrogen bonds, supporting direct interaction potential. - Experimental validation showed SOP reduced PTPN1 mRNA levels; PTPN1 knockdown reproduced SOP's antiproliferative effect and combining knockdown with SOP produced no additive suppression, indicating PTPN1 is a required downstream mediator. - The study presents SOP as a compound that restrains pancreatic cancer cell proliferation and proposes PTPN1 as a promising therapeutic biomarker and target; this is described as the first report integrating these computational and functional approaches for SOP in pancreatic cancer. - The paper used an integrated multi-omics and computational pharmacology pipeline with experimental validation; detailed experimental parameters (e.g., concentrations, time points, statistical values) were not reported in the abstract and are not available in the source excerpt.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42814531/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42814531%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42814531/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42814531/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42814531/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42814531/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42814531/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42814531%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42814531%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42814531/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42814531/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42814531/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42814531/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42814531/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42814531/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42814531/#abstract) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42814531/#references) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42814531/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42814531/#substances) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42814531/#grants) Title & authors Abstract References MeSH terms Substances Grants and funding Chem Biodivers Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Chem+Biodivers%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Chem+Biodivers%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) . 2026 Oct;23(10):e71778. doi: 10.1002/cbdv.71778. # Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer [Peng Lin](https://pubmed.ncbi.nlm.nih.gov/?term=Lin+P&cauthor_id=42814531)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814531/#full-view-affiliation-1 "Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, P. R. China."), [Wei Cheng](https://pubmed.ncbi.nlm.nih.gov/?term=Cheng+W&cauthor_id=42814531)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42814531/#full-view-affiliation-2 "College of Pharmaceutical Sciences, Southwest University, Chongqing, P. R. China."), [Xin Qi](https://pubmed.ncbi.nlm.nih.gov/?term=Qi+X&cauthor_id=42814531)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814531/#full-view-affiliation-1 "Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, P. R. China."), [Jing Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+J&cauthor_id=42814531)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814531/#full-view-affiliation-1 "Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, P. R. China.") Affiliations Expand ### Affiliations * 1 Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, P. R. China. * 2 College of Pharmaceutical Sciences, Southwest University, Chongqing, P. R. China. * PMID: **42814531** * DOI: [ 10.1002/cbdv.71778 ](https://doi.org/10.1002/cbdv.71778) Item in Clipboard # Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer Peng Lin et al. Chem Biodivers. 2026 Oct. Show details Display options Display options Format Abstract PubMed PMID Chem Biodivers Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Chem+Biodivers%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Chem+Biodivers%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) . 2026 Oct;23(10):e71778. doi: 10.1002/cbdv.71778. ### Authors [Peng Lin](https://pubmed.ncbi.nlm.nih.gov/?term=Lin+P&cauthor_id=42814531)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814531/#short-view-affiliation-1 "Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, P. R. China."), [Wei Cheng](https://pubmed.ncbi.nlm.nih.gov/?term=Cheng+W&cauthor_id=42814531)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42814531/#short-view-affiliation-2 "College of Pharmaceutical Sciences, Southwest University, Chongqing, P. R. China."), [Xin Qi](https://pubmed.ncbi.nlm.nih.gov/?term=Qi+X&cauthor_id=42814531)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814531/#short-view-affiliation-1 "Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, P. R. China."), [Jing Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+J&cauthor_id=42814531)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814531/#short-view-affiliation-1 "Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, P. R. China.") ### Affiliations * 1 Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, P. R. China. * 2 College of Pharmaceutical Sciences, Southwest University, Chongqing, P. R. China. * PMID: **42814531** * DOI: [ 10.1002/cbdv.71778 ](https://doi.org/10.1002/cbdv.71778) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Pancreatic cancer has a dismal prognosis and limited therapeutic options, highlighting an urgent need for effective treatments. Sophoricoside (SOP), a natural isoflavone glycoside, has exhibited anticancer activities in multiple malignancies, including lung cancer, glioblastoma, and hepatocellular carcinoma. We combined cellular assays, network pharmacology, machine learning, and multi-omics to investigate SOP's effects. SOP-inhibited proliferation of MIA PaCa-2, SW1990, and PANC-1 cells dose-dependently. Network pharmacology revealed 85 overlapping targets enriched in MAPK, apoptosis, and PD-L1/PD-1 pathways. Machine learning and differential expression identified PTPN1 as the core target. PTPN1 was markedly upregulated in pancreatic adenocarcinoma, and its high expression correlated with poor survival and immune infiltration. Functional enrichment linked PTPN1 to TGF-β, VEGF, and metabolic reprogramming. Molecular docking suggested a possible binding mode between SOP and PTPN1, involving four predicted hydrogen bonds. SOP reduced PTPN1 mRNA, and PTPN1 knockdown phenocopied SOP's antiproliferative effect with no additivity upon combination. Collectively, this first report demonstrates that SOP restrains pancreatic cancer cell proliferation, with PTPN1 identified as a key functionally required downstream mediator based on integrative computational and functional evidence. This work offers an integrated strategy for mechanistic exploration and highlights PTPN1 as a promising therapeutic biomarker and target for pancreatic cancer. **Keywords:** PTPN1; machine learning; network pharmacology; pancreatic cancer; proliferation; sophoricoside. © 2026 The Author(s). Chemistry & Biodiversity published by Wiley‐VHCA AG. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## References 1. 1. D. Ansari, B. Tingstedt, B. Andersson, et al., “Pancreatic Cancer: Yesterday, Today and Tomorrow,” Future Oncology 12, no. 16 (2016): 1929–1946, [https://doi.org/10.2217/fon‐2016‐0010](https://doi.org/10.2217/fon%E2%80%902016%E2%80%900010). 2. 1. N. Akizuki, K. Shimizu, M. Asai, et al., “Prevalence and Predictive Factors of Depression and Anxiety in Patients with Pancreatic Cancer: A Longitudinal Study,” Japanese Journal of Clinical Oncology 46, no. 1 (2016): 71–77, . 3. 1. E. Brozos‐Vázquez, M. Toledano‐Fonseca, N. Costa‐Fraga, et al., “Pancreatic Cancer Biomarkers: A Pathway to Advance in Personalized Treatment Selection,” Cancer Treatment Reviews 125 (2024): 102719, . 4. 1. X. Chen, H. J. Zeh, R. Kang, G. Kroemer, and D. Tang, “Cell Death in Pancreatic Cancer: From Pathogenesis to Therapy,” Nature Reviews Gastroenterology & Hepatology 18, no. 11 (2021): 804–823, [https://doi.org/10.1038/s41575‐021‐00486‐6](https://doi.org/10.1038/s41575%E2%80%90021%E2%80%9000486%E2%80%906). 5. 1. S. P. Hussain, “Pancreatic Cancer: Current Progress and Future Challenges,” International Journal of Biological Sciences 12, no. 3 (2016): 270–272, . Show all 55 references ## MeSH terms * Antineoplastic Agents, Phytogenic* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2C+Phytogenic%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents%2C+Phytogenic) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Antineoplastic Agents, Phytogenic* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2C+Phytogenic%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents%2C+Phytogenic) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Benzopyrans* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Benzopyrans%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Benzopyrans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Benzopyrans* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Benzopyrans%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Benzopyrans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Cell Line, Tumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Line%2C+Tumor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Line%2C+Tumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Cell Proliferation / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Proliferation%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Proliferation) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Dose-Response Relationship, Drug Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Dose-Response+Relationship%2C+Drug%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Dose-Response+Relationship%2C+Drug) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Drug Screening Assays, Antitumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Screening+Assays%2C+Antitumor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Screening+Assays%2C+Antitumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Molecular Docking Simulation Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Molecular+Docking+Simulation%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Molecular+Docking+Simulation) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Multiomics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Multiomics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Multiomics) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Network Pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Network+Pharmacology%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Network+Pharmacology) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Pancreatic Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pancreatic+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pancreatic+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Pancreatic Neoplasms* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pancreatic+Neoplasms%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pancreatic+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Pancreatic Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pancreatic+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pancreatic+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Protein+Tyrosine+Phosphatase%2C+Non-Receptor+Type+1%2Fantagonists+and+inhibitors%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Protein+Tyrosine+Phosphatase%2C+Non-Receptor+Type+1) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Protein Tyrosine Phosphatase, Non-Receptor Type 1 / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Protein+Tyrosine+Phosphatase%2C+Non-Receptor+Type+1%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Protein+Tyrosine+Phosphatase%2C+Non-Receptor+Type+1) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Protein Tyrosine Phosphatase, Non-Receptor Type 1 / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Protein+Tyrosine+Phosphatase%2C+Non-Receptor+Type+1%2Fmetabolism%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Protein+Tyrosine+Phosphatase%2C+Non-Receptor+Type+1) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) ## Substances * Protein Tyrosine Phosphatase, Non-Receptor Type 1 Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Protein+Tyrosine+Phosphatase%2C+Non-Receptor+Type+1%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Protein+Tyrosine+Phosphatase%2C+Non-Receptor+Type+1%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814531/) * Benzopyrans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Benzopyrans%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in M
## Related Clinical Research

- [Integrative oncology works for cancer symptoms — insurers lag on coverage](https://medichelpline.com/clinical-feed/stat-news-4-opinion-the-science-on-relieving-cancer-symptoms-is-clear-why-isn-t-insurance.md)
- [Emotional distress and immune checkpoint inhibitor efficacy in hepatocellular carcinoma: multicent](https://medichelpline.com/clinical-feed/bmj-open-1-association-between-emotional-distress-and-efficacy-of-immune-checkpoint.md)
- [Exercise Dose and Depression in Lung Cancer: Meta-analysis Finds Benefit at ~602 MET-min/week](https://medichelpline.com/clinical-feed/pubmed-43064838.md) (DOI: 10.1007/s00520-026-11497-x)
- [Physical activity intensity linked to lower self-reported emphysema in older US adults (NHANES ana](https://medichelpline.com/clinical-feed/plos-one-5-association-between-physical-activity-intensity-and-self-reported-emphysema-a.md)
- [New Multi-Society Framework Defines Female Life Stages for Heart Health](https://medichelpline.com/clinical-feed/aha-news-2-leading-health-groups-redefine-heart-health-for-girls-and-women.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.